<DOC>
	<DOCNO>NCT00768846</DOCNO>
	<brief_summary>The zotarolimus-eluting Endeavor Resolute stent inferior everolimus- elute Xience V stent platform regard composite cardiac death , myocardial infarction target lesion revascularisation real-world population .</brief_summary>
	<brief_title>Zotarolimus Everolimus-Eluting Stents ProsPectively Compared Real World</brief_title>
	<detailed_description>The use stents become common practice percutaneous treatment coronary artery disease . Restenosis affect 20-40 % de novo coronary lesion treat bare metal stent . Drug-eluting stent ( DES ) emerge effective strategy prevention restenosis . The first available DES Sirolimus-eluting Cypher Paclitaxel-eluting Taxus stent . Although mid-term efficacy well-established , ongoing debate potential increase incidence late stent thrombosis , well delay onset restenosis catch-up phenomenon DES . Recent evidence demonstrates might difference various DES term safety efficacy . The difference might relate drug , polymer stent design . Everolimus ( SDZ-RAD ) zotarolimus ( ABT-578 ) new antiproliferative agent share common structural biological property sirolimus ( `` limus-group '' ) . Both drug bind intracellular sirolimus receptor , FK 506-binding protein 12 ( FKBP 12 ) . The drug-FKBP12 complex inhibits cell cycle progression via inactivation mammalian target Rapamycin ( mTOR ) thereby regulate vascular smooth muscle cell migration proliferation . Preclinical study show improved endothelialization limit chronic inflammation everolimus-eluting stent compare previous drug-eluting stent . Moreover , first randomize clinical trial everolimus-eluting stent show promising result regard safety , feasibility efficacy suppression neointimal proliferation . Safety efficacy zotarolimus-eluting Endeavor stent investigate Endeavor clinical program . In Endeavor III IV trial , Endeavour stent prove inferior Cypher Taxus stent regard angiographic endpoint . However , rate target vessel failure similar group . The Endeavor RESOLUTE stent platform use new polymer potential improvement drug release compare Endeavor stent . The RESOLUTE clinical trial first-in man , observational , uncontrolled , non-randomized study evaluate Endeavor Resolute drug-eluting stent new polymer . The trial enrol total 130 patient native coronary artery lesion . There data available compare zotarolimus-eluting Endeavor Resolute stent everolimus-eluting Xience V stent . Thus aim prospective , randomize study compare efficacy safety two `` new generation '' drug-eluting stent platform real world population .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patients older 18 year symptomatic coronary artery disease undergo PCI stent implantation . Written , inform consent patient her/his legallyauthorized representative participation study . Cardiogenic shock . Malignancies comorbid condition ( example severe liver , renal pancreatic disease ) life expectancy le 12 month may result protocol noncompliance . Known allergy study medication : everolimus , zotarolimus , cobalt chrome . Inability take clopidogrel least 6 month . Pregnancy ( present , suspected plan ) positive pregnancy test . ( In woman childbearing potential pregnancy test mandatory . ) Previous enrollment trial . Patient 's inability fully cooperate study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>PCI</keyword>
	<keyword>Stent</keyword>
	<keyword>DES</keyword>
	<keyword>CAD</keyword>
</DOC>